Details of the Drug

General Information of Drug (ID: DMDP6UF)

Drug Name
SCH-721015
Synonyms RAd-IFN, Merck & Co; RAd-IFN, Schering-Plough; Ad.hIFN-alpha2b, Merck & Co; Recombinant adenovirus vector expressing hybrid-interferon (bladder neoplasm), Merck & Co
Indication
Disease Entry ICD 11 Status REF
Mesothelioma 2C51.2 Phase 1 [1]
Cross-matching ID
TTD ID
D0NI0X

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interferon-alpha 2 (IFNA2) TTSIUJ9 IFNA2_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Mesothelioma
ICD Disease Classification 2C51.2
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interferon-alpha 2 (IFNA2) DTT IFNA2 9.31E-04 0.35 2.05
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01162785) Phase IB Intravesical Administration of SCH 721015. U.S. National Institutes of Health.
2 Toxicity and exposure of an adenovirus containing human interferon alpha-2b following intracystic administration in cynomolgus monkeys. Gene Ther. 2012 Jul;19(7):742-51.